Cardiovascular diseases that develop from hypercholesterolemia-induced atherosclerosis have emerged as a significant threat to human health.Recently,probiotics exhibiting cholesterol-lowering properties have emerged as a prominent area of research.Numerous studies have demonstrated that Lactobacillus reuteri can effectively reduce endogenous cholesterol synthesis,regulate cholesterol transport,and promote cholesterol degradation by modulating the expression of key genes,such as sterol-regulatory element binding protein 2,3-hydroxy-3-methyl-glutaryl coenzyme A reductase,and cholesterol 7 alpha-hydroxylase,in both the liver and intestinal epithelial cells of the host.This leads to a notable decrease in total cholesterol and low-density lipoprotein cholesterol levels in the host serum.The present paper offers a comprehensive overview of the underlying mechanisms responsible for the cholesterol-lowering effects exerted by L.reuteri,aiming to provide valuable insights into the treatment of hypercholesterolemia and the development of probiotics with cholesterol-lowering properties.

Objective:To identify the risk factors influencing the prognosis of patients with advanced breast cancer through LASSO-Logistic regression analysis and construct a nomogram model to evaluate their prognostic risk.Methods:A total of 178 patients with advanced breast cancer who visited the Department of Thyroid and Breast Surgery of Chengyang District People’s Hospital of Qingdao City from Jan. 2015 to Jan. 2023 were selected as the research subjects. According to the follow-up results, the patients were divided into a good-prognosis group and a poor-prognosis group. Clinical data of the patients were collected. LASSO-Logistic regression analysis was used to identify the risk factors affecting the prognosis of patients with advanced breast cancer. A nomogram model was constructed based on the analysis results. The predictive efficacy of the model for the prognostic risk of patients with advanced breast cancer was evaluated using the receiver operating characteristic (ROC) curve and Hosmer-Lemeshow (H-L) test.Results:During the follow-up, 5 patients were lost to follow-up. Among the final 173 patients included, 60 had poor prognoses (accounting for 34.68%), and 113 had good prognoses (accounting for 65.32%). There were significant differences between the poor prognosis group and the good prognosis group in terms of the number of lymph node metastases ( χ 2=18.12), the number of organ metastases ( χ 2=14.28), the difference in ADC before and after treatment ( t=17.35), the difference in SER before and after treatment ( t=9.57), the enhancement of the echo behind the breast after treatment ( χ 2=13.00), and the proportion of increased calcification ( χ 2=8.06) (both P < 0.05). The clinical data with significant differences in the univariate analysis were included in the LASSO regression analysis. Six factors were finally selected: number of lymph node metastases > 5, number of organ metastases > 1, difference in ADC values before and after treatment, difference in SER values before and after treatment, enhanced echo behind the breast, and increased calcification. These six factors selected by LASSO regression were included in the Logistic regression analysis. The results showed that number of organ metastases > 1 ( OR=2.208, 95% CI: 1.153-3.263), small difference in ADC values before and after treatment ( OR=0.448, 95% CI: 0.287-0.608), enhanced echo behind the breast ( OR=2.474, 95% CI: 1.063-3.886), and increased calcification ( OR=3.762, 95% CI: 1.831-5.693) were independent risk factors for poor prognosis in patients with advanced breast cancer (both P<0.05). A nomogram model was constructed based on the analysis results. The ROC curve showed that the area under the curve (AUC) of the model was 0.778. The H-L test results showed that the calibration curve fit well with the ideal curve, with χ 2 = 0.69 and P = 0.273. Conclusion:The nomogram model constructed based on LASSO-Logistic regression analysis has good predictive efficacy for the prognosis of patients with advanced breast cancer.

Objective:To identify the risk factors influencing the prognosis of patients with advanced breast cancer through LASSO-Logistic regression analysis and construct a nomogram model to evaluate their prognostic risk.Methods:A total of 178 patients with advanced breast cancer who visited the Department of Thyroid and Breast Surgery of Chengyang District People’s Hospital of Qingdao City from Jan. 2015 to Jan. 2023 were selected as the research subjects. According to the follow-up results, the patients were divided into a good-prognosis group and a poor-prognosis group. Clinical data of the patients were collected. LASSO-Logistic regression analysis was used to identify the risk factors affecting the prognosis of patients with advanced breast cancer. A nomogram model was constructed based on the analysis results. The predictive efficacy of the model for the prognostic risk of patients with advanced breast cancer was evaluated using the receiver operating characteristic (ROC) curve and Hosmer-Lemeshow (H-L) test.Results:During the follow-up, 5 patients were lost to follow-up. Among the final 173 patients included, 60 had poor prognoses (accounting for 34.68%), and 113 had good prognoses (accounting for 65.32%). There were significant differences between the poor prognosis group and the good prognosis group in terms of the number of lymph node metastases ( χ 2=18.12), the number of organ metastases ( χ 2=14.28), the difference in ADC before and after treatment ( t=17.35), the difference in SER before and after treatment ( t=9.57), the enhancement of the echo behind the breast after treatment ( χ 2=13.00), and the proportion of increased calcification ( χ 2=8.06) (both P < 0.05). The clinical data with significant differences in the univariate analysis were included in the LASSO regression analysis. Six factors were finally selected: number of lymph node metastases > 5, number of organ metastases > 1, difference in ADC values before and after treatment, difference in SER values before and after treatment, enhanced echo behind the breast, and increased calcification. These six factors selected by LASSO regression were included in the Logistic regression analysis. The results showed that number of organ metastases > 1 ( OR=2.208, 95% CI: 1.153-3.263), small difference in ADC values before and after treatment ( OR=0.448, 95% CI: 0.287-0.608), enhanced echo behind the breast ( OR=2.474, 95% CI: 1.063-3.886), and increased calcification ( OR=3.762, 95% CI: 1.831-5.693) were independent risk factors for poor prognosis in patients with advanced breast cancer (both P<0.05). A nomogram model was constructed based on the analysis results. The ROC curve showed that the area under the curve (AUC) of the model was 0.778. The H-L test results showed that the calibration curve fit well with the ideal curve, with χ 2 = 0.69 and P = 0.273. Conclusion:The nomogram model constructed based on LASSO-Logistic regression analysis has good predictive efficacy for the prognosis of patients with advanced breast cancer.

Cardiovascular diseases that develop from hypercholesterolemia-induced atherosclerosis have emerged as a significant threat to human health.Recently,probiotics exhibiting cholesterol-lowering properties have emerged as a prominent area of research.Numerous studies have demonstrated that Lactobacillus reuteri can effectively reduce endogenous cholesterol synthesis,regulate cholesterol transport,and promote cholesterol degradation by modulating the expression of key genes,such as sterol-regulatory element binding protein 2,3-hydroxy-3-methyl-glutaryl coenzyme A reductase,and cholesterol 7 alpha-hydroxylase,in both the liver and intestinal epithelial cells of the host.This leads to a notable decrease in total cholesterol and low-density lipoprotein cholesterol levels in the host serum.The present paper offers a comprehensive overview of the underlying mechanisms responsible for the cholesterol-lowering effects exerted by L.reuteri,aiming to provide valuable insights into the treatment of hypercholesterolemia and the development of probiotics with cholesterol-lowering properties.

To explore the clinical effect, safety and effectiveness of ultrasound-guided rhomboid intercostal and subserratus plane (RISS) block for postoperative analgesia after minimally invasive McKeown esophagectomy (MIE-McKeown), and provide new ideas for the selection of postoperative analgesia programs for minimally invasive esophageal cancer surgery patients.

Objective:To investigate the expression of programmed death ligand 1 (PD-L1) in rectal cancer tissues and the correlation of PD-L1 expression with clinicopathological characteristics and overall survival of patients.Methods:The clinical data of 200 newly treated rectal cancer patients in Shanxi Provincial Cancer Hospital from January 2014 to December 2015 were retrospectively analyzed. The expression of PD-L1 in rectal cancer tissues was detected by immunohistochemistry. The correlations of PD-L1 expression with gender, age, tumor T stage, lymph node metastasis, tumor differentiation, histological type, tumor TNM stage, neutrophil-to-lymphocyte ratio (NLR) and overall survival of patients were analyzed.Results:The positive expression rate of PD-L1 was 24% (48/200). The positive expression rate of PD-L1 was high in patients with lymph node metastasis and high NLR (≥ 3.5) (both P < 0.05). The 5-year overall survival rate in PD-L1-positive group was 42%, and the PD-L1-negative group was 59%, and the difference between the two groups was statistically significant ( P < 0.05). The results of multivariate analysis showed that lymph node metastasis ( HR = 3.456, 95% CI 2.148-5.556, P < 0.01), NLR ≥ 3.5 ( HR = 1.871, 95% CI 1.169-2.996, P = 0.009), and PD-L1-positive expression ( HR = 2.187, 95% CI 1.373-3.484, P = 0.001) were independent adverse influencing factors for the overall survival of rectal cancer patients. Conclusion:PD-L1 is highly expressed in rectal cancer tissues, and the positive expression of PD-L1 is associated with poor overall survival of patients.

In view of the current teaching status of Traditional Rehabilitation Methodology for rehabilitation medicine specialty in higher medical colleges and universities,combining with the knowledge of some acupoints taught in this course,we put forward some suggestions for the teaching of this course.In teaching process of acupoints knowledge,while emphasizing the importance of its anatomical location,we should also attach importance to elaborating the name of acupoints and the rich cultural contents contained in the naming process.At the same time,paying attention to induction learning and finding memory rules,combining theoretical knowledge with classmates' hands-on practice,and encouraging students to participate early in clinical practice activities,we can develop students' practical work ability.

Objective: To verify the safety and efficacy of IONTRIS particle therapy system (IONTRIS) in clinical implementation. Methods: Between 6.2014 and 8.2014, a total of 35 patients were enrolled into this trial: 31 males and 4 females with a median age of 69 yrs (range 39-80). Ten patients had locally recurrent head and neck tumors after surgery, 4 cases with thoracic malignancies, 1 case with hepatocellular carcinoma, 1 case with retroperitoneal sarcoma, and 19 cases with non-metastatic prostate carcinomas. Phantom dose verification was mandatory for each field before the start of radiation. Results: Twenty-two patients received carbon ion and 13 had proton irradiation. With a median follow-up time of 1 year, all patients were alive. Among the 16 patients with head and neck, thoracic, and abdominal/pelvic tumors, 2, 1, 12, and 1 cases developed complete response, partial response, stable disease, or disease progression, respectively. Progression-free survival rate was 93.8% (15/16). Among the 19 patients with prostate cancer, biological-recurrence free survival was 100%. Particle therapy was well tolerated in all 35 patients. Twenty-five patients (71.4%) experienced 33 grade 1 acute adverse effects, which subsided at 1 year follow-up. Six (17.1%) patients developed grade 1 late adverse effects. No significant change in ECOG or body weight was observed. Conclusions IONTRIS is safe and effective for clinical use. However, long term follow-up is needed to observe the late toxicity and long term result.

Objective To verify the safety and efficacy of IONTRIS particle therapy system ( IONTRIS) in clinical implementation. Methods Between 6.2014 and 8.2014, a total of 35 patients were enrolled into this trial:31 males and 4 females with a median age of 69 yrs ( range 39?80) . Ten patients had locally recurrent head and neck tumors after surgery, 4 cases with thoracic malignancies, 1 case with hepatocellular carcinoma, 1 case with retroperitoneal sarcoma, and 19 cases with non?metastatic prostate carcinomas. Phantom dose verification was mandatory for each field before the start of radiation. Results Twenty?two patients received carbon ion and 13 had proton irradiation. With a median follow?up time of 1 year, all patients were alive. Among the 16 patients with head and neck, thoracic, and abdominal/pelvic tumors, 2, 1, 12, and 1 cases developed complete response, partial response, stable disease, or disease progression, respectively. Progression?free survival rate was 93.8％ (15/16). Among the 19 patients with prostate cancer, biological?recurrence free survival was 100％. Particle therapy was well tolerated in all 35 patients. Twenty?five patients (71.4％) experienced 33 grade 1 acute adverse effects, which subsided at 1 year follow?up. Six ( 17.1％) patients developed grade 1 late adverse effects. No significant change in ECOG or body weight was observed. Conclusions IONTRIS is safe and effective for clinical use. However, long term follow?up is needed to observe the late toxicity and long term result.

Objective To verify the safety and efficacy of IONTRIS particle therapy system ( IONTRIS) in clinical implementation. Methods Between 6.2014 and 8.2014, a total of 35 patients were enrolled into this trial:31 males and 4 females with a median age of 69 yrs ( range 39?80) . Ten patients had locally recurrent head and neck tumors after surgery, 4 cases with thoracic malignancies, 1 case with hepatocellular carcinoma, 1 case with retroperitoneal sarcoma, and 19 cases with non?metastatic prostate carcinomas. Phantom dose verification was mandatory for each field before the start of radiation. Results Twenty?two patients received carbon ion and 13 had proton irradiation. With a median follow?up time of 1 year, all patients were alive. Among the 16 patients with head and neck, thoracic, and abdominal/pelvic tumors, 2, 1, 12, and 1 cases developed complete response, partial response, stable disease, or disease progression, respectively. Progression?free survival rate was 93.8％ (15/16). Among the 19 patients with prostate cancer, biological?recurrence free survival was 100％. Particle therapy was well tolerated in all 35 patients. Twenty?five patients (71.4％) experienced 33 grade 1 acute adverse effects, which subsided at 1 year follow?up. Six ( 17.1％) patients developed grade 1 late adverse effects. No significant change in ECOG or body weight was observed. Conclusions IONTRIS is safe and effective for clinical use. However, long term follow?up is needed to observe the late toxicity and long term result.